In inflammatory bowel disease models including ulcerative colitis and cysteamine-induced colitis, BPC-157 reduces inflammatory markers (IL-6, TNF-, IL-1), improves mucosal architecture, and accelerates healing of damaged intestinal tissue
Corresponding ACR50 and ACR70 responses also favored golimumab (44% and 25%, compared with 6% and 2%)
Any treatment can interact with existing medications or supplements, so its important to share a complete list of everything you take including prescriptions, over-the-counter products, vitamins, and herbal supplements during your consultation
Shelf life varies by peptide sequence and amino acid composition
For this reason, findings should be interpreted according to the evidence available for each individual peptide rather than assumed to apply directly to the blend
MobiSystems, Inc